ARMD indicates age-related macular degeneration; CNV, choroidal neovascularization; and EMB, epimacular brachytherapy.
aOne participant in the ranibizumab monotherapy group did not receive the intervention as randomized because they withdrew consent prior to baseline and were found to be ineligible because of prior photodynamic therapy. Two participants in the EMB group were enrolled in error; one had previous vitrectomy and the other had visual acuity worse than 6/96.